Danaher (DHR) 2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-24) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (served as auditor since 2002)

Fiscal Year: 2025 (ended December 31, 2025)

One-line verdict: Danaher's 2025 10-K tells a transitional story — the Biotechnology segment's bioprocessing engine re-accelerated to 8% segment growth while the Diagnostics and Life Sciences segments were largely flat, producing 2.9% total revenue growth to $24.57B. Net earnings from continuing operations declined to "approximately $3.6 billion or $5.03 per diluted common share, compared to approximately $3.9 billion or $5.29 per diluted common share" on the back of 2025 intangible asset impairments totaling $562M per the segment disclosure. Cash flow quality is strong (CFFO/NI of 1.78, FCF of $5.26B), the Beneish M-Score is clean at -2.57, and Altman Z-Score is 4.45 in the safe zone. The F grade is entirely driven by two balance sheet mechanics: $61.0B of goodwill plus intangibles against $52.5B of equity (116% ratio), the legacy of the Cytiva, Pall, Aldevron, Abcam and Beckman Coulter acquisitions, plus $19.7B of gross debt against only $4.6B of cash (23% coverage). E&Y's Critical Audit Matter is Uncertain Tax Positions — standard for a multinational — and the 10-K discloses a pending acquisition of Masimo Corporation that will add further goodwill to the balance sheet if completed.

Three Segments and the 2025 Revenue Picture

The 10-K's segment footnote discloses total sales of $24,568M for 2025 (up from $23,875M in 2024 and $23,890M in 2023):

The 10-K explains the Biotechnology re-acceleration: "Biotechnology segment sales increased 8.0% primarily as a result of increased core sales in the bioprocessing business, and to a lesser extent, the impact of currency exchange rates. The year-over-year increase in core sales was led by increased sales of consumables, partially offset by declines in equipment sales. Geographically, the increase in core sales was led by North America and Western Europe."

The Diagnostics segment: "Sales of respiratory tests. The Company believes that demand for respiratory tests in the second half of 2025 was driven in part by customers purchasing in preparation for the respiratory season and if the respiratory season is less severe than anticipated, demand may be adversely impacted." This is the first time Danaher has flagged respiratory-test inventory timing as a risk for 2026.

Net earnings: "The Company's net earnings from continuing operations for the year ended December 31, 2025 totaled approximately $3.6 billion or $5.03 per diluted common share, compared to approximately $3.9 billion or $5.29 per diluted common share for the year ended December 31, 2024. 2025 intangible asset impairments net of 2024 intangible asset impairments, increased other expenses and decreased interest income, net of increased gross profit, drove the year-over-year decline in net earnings from continuing operations and diluted net earnings per common share from continuing operations."

The Acquisition History Is the Balance Sheet

The 10-K identifies the key portfolio building blocks in its Life Sciences segment narrative: "Beckman Coulter in 2011, Pall in 2015, Phenomenex in 2016, IDT in 2018, Aldevron in 2021 and Abcam in 2023." And for Biotechnology: "the bioprocessing business and the discovery and medical business. The bioprocessing business is a leading provider of technologies, consumables, services and solutions that advance, accelerate and integrate the development and manufacture of therapeutics" — this is Cytiva, acquired in 2020 from GE for $21.4B, the single largest transaction in Danaher's history.

The Diagnostics segment: "Danaher established the diagnostics business in 2004 through the acquisition of Radiometer and expanded the business through numerous subsequent acquisitions, including Cepheid in 2016. The Diagnostics segment consists of the molecular diagnostics business and the clinical diagnostics businesses."

Critically, Note 2 describes a pending acquisition: "Our acquisition of businesses (including our pending acquisition of Masimo Corporation), investments, joint ventures and other strategic relationships can also negatively impact our business and financial statements and our indemnification rights may not fully protect us from liabilities related thereto." The pending Masimo deal will add further goodwill and intangibles to an already-large acquired-asset base.

Balance Sheet: $61.0B Goodwill+Intangibles on $52.5B Equity

The screening engine flags: "Goodwill+Intangibles $61.0B = 116% of equity. Over 50%." This is a FAIL on check D1.

Danaher is a classic serial acquirer. The $43.2B of goodwill is the cumulative cost of Beckman Coulter ($6.8B in 2011), Pall ($13.6B in 2015), Cytiva/GE Biopharma ($21.4B in 2020), Aldevron ($9.6B in 2021), and Abcam ($5.7B in 2023), plus numerous smaller acquisitions. Total assets per the 10-K segment disclosure: Biotechnology $37.3B, Life Sciences $23.1B, Diagnostics $14.7B, Other $8.3B — a total of $83.5B. Goodwill and intangibles represent about 73% of identifiable assets.

Critically, the 10-K's segment disclosure shows intangible asset impairments of $562M in 2025 ($101M Biotechnology, $446M Life Sciences, $15M Other), up from $265M in 2024 ($222M Biotechnology, $43M Life Sciences). The $446M Life Sciences impairment is the largest single charge and is consistent with the "2025 intangible asset impairments" cited in the MD&A as a driver of the earnings decline. The Life Sciences impairment points to difficulty for pieces of the Abcam/IDT/Aldevron portfolio to meet their post-acquisition forecasts.

The 10-K describes the impairment testing protocol: "For goodwill impairment testing, the Company estimates the fair value of its reporting units primarily using a market-based approach as well as an income approach in certain instances to corroborate value. The market-based approach relies on current trading multiples of forecasted EBITDA for companies operating in businesses similar to each of the Company's reporting units..."

Debt and Leverage

The screening engine flags: "Cash $4.6B covers only 23% of debt $19.7B." This is a FAIL on C4. However, D2 passes: "Debt/EBITDA = 2.8x. Healthy" and interest coverage is a robust 17.7x.

Cash more than doubled from $2.1B to $4.6B in 2025 — a 122% increase. The rising cash balance likely reflects preparation for the Masimo acquisition. Total debt rose from $17.1B to $19.7B (+15%) as the Company prepared its funding strategy; the 10-K references "the Company had no variable-rate debt obligations" as of December 31, 2025, and that commercial paper fills short-term needs. The Masimo deal, once completed, is expected to add meaningful new debt.

Cash Flow: The Cleanest Part of the Report

The screening engine passes all four cash quality checks. C1: "CFFO/NI = 1.78. Profits backed by cash." C2: "FCF $5.3B, FCF/NI = 1.46." C3: "Accruals ratio = -3.4%. Low accruals." Only C4 fails on the cash-to-debt ratio discussed above.

CFFO of $6.4B is down modestly from $6.7B but remains robust. FCF of $5.26B against $24.6B revenue is a 21% FCF margin — among the strongest in healthcare diagnostics and life sciences. The 10-K attributes the modest CFFO decline to timing differences; net working capital was a modest use of cash in 2025 versus a bigger benefit in 2024.

Gross margin: the screening engine reports 59.1% (2024: 59.5%). The 10-K describes a focused effort on pricing: "gross profit margins, expand and improve the effectiveness of the Company's sales force, continue to reduce costs and improve operating efficiency and quality, and effectively address the demands of an increasingly regulated global environment and the rapidly evolving trade environment."

The AR Watch Flag and Tariff Exposure

The screening engine flags A2 as a WATCH: "AR growth 10.6% exceeds revenue growth 2.9%." Trade accounts receivable grew from $3,537M in 2024 to $3,913M in 2025 (+10.6%) while revenue grew only 2.9%. DSO rose from 54 days to 58 days. This is a modest deterioration but not yet a fail (the engine requires two consecutive years).

The 10-K directly addresses the tariff situation, which may explain some of the pattern: "Danaher operates a diversified global supply chain and sources parts and materials globally. Since early 2025, the U.S. government has implemented significant new tariffs on imports from a wide range of countries, which has also prompted retaliatory tariffs and other actions by a number of countries, including tariffs and export restrictions on certain manufacturing components imposed by China and tariffs pursuant to trade agreements the U.S. has entered into with certain countries."

And on the profitability side: "operating profit impact of the enacted tariffs with manufacturing footprint changes, supply chain adjustments, surcharges and additional productivity and cost savings actions. To the extent the Company is unable to continue to largely offset the incremental cost from the enacted tariffs, enacted or threatened tariffs negatively impact future demand or the export restrictions negatively impact manufacturing, the Company's revenue and profitability would be adversely impacted."

Tariff exposure is being explicitly managed and largely offset for now, but the 10-K warns it is a live operational risk.

M-Score: Clean Signal Across All Components

F-Score returns 1.63, probability of misstatement 0.60% (low). Altman Z-Score is 4.45 with a very strong X4 (equity/liabilities = 1.70), reflecting Danaher's equity base and modest leverage.

Auditor's Critical Audit Matter — Uncertain Tax Positions

Ernst & Young LLP issued an unqualified opinion. The auditor report says explicitly: "We have served as the Company's auditor since 2002. Tysons, Virginia. February 24, 2026."

The Critical Audit Matter is Uncertain Tax Positions, and the 10-K reproduces E&Y's description: "As discussed in Note 7 to the consolidated financial statements, the Company operates in the U.S. and multiple international tax jurisdictions and as a result files numerous tax returns in those locations. Uncertainty in a tax position may arise for multiple reasons, including because tax laws are subject to interpretation. The Company applies the applicable tax law and judgment to (1) determine whether, based on the technical merits, a tax position is more likely than not to be sustained and (2) measure the amount of tax benefit that qualifies for recognition. As of December 31, 2025, the Company's gross unrecognized tax benefits related to uncertain tax positions were approximately $1.3 billion."

$1.3B in unrecognized tax benefits is material against $3.6B in net earnings — about 36% of net income. This is the common CAM for a multinational operating in ~50 countries as Danaher does ("research and development, manufacturing, sales, distribution, service and administrative facilities are located in approximately 50 countries"). E&Y used "tax subject matter resources" to audit it.

The 18-Point Screening

Revenue Quality

Expense Quality

Cash Flow Quality

Balance Sheet

Acquisition Risk

Manipulation Score

Additional Scores: F-Score probability of misstatement 0.60% (low). Altman Z-Score 4.45 (safe zone, strong X4 = 1.70).

Key Risks from the 10-K

1. $562M Intangible Asset Impairments in 2025 — The segment disclosure shows $446M in Life Sciences and $101M in Biotechnology impairments in 2025, up from $265M total in 2024. The MD&A attributes the YoY earnings decline to "2025 intangible asset impairments net of 2024 intangible asset impairments, increased other expenses and decreased interest income, net of increased gross profit..." This is a warning shot on some acquired portfolio pieces failing to meet post-acquisition projections.

2. Pending Masimo Acquisition — The 10-K repeatedly references "our pending acquisition of Masimo Corporation" in the Notes and Risk Factors. Masimo is a patient-monitoring technology company; the deal will add goodwill, intangibles, and debt. Integration risk and antitrust review remain live.

3. Tariff Exposure — Explicitly called out: "Since early 2025, the U.S. government has implemented significant new tariffs... In February 2026, [the environment continues to evolve]." Danaher is "largely offsetting" the tariff impact through manufacturing footprint changes, surcharges, and productivity, but the 10-K warns of future revenue and profitability impact if offsets cannot continue.

4. Respiratory Test Timing Risk — The Diagnostics segment explicitly warns: "Sales of respiratory tests. The Company believes that demand for respiratory tests in the second half of 2025 was driven in part by customers purchasing in preparation for the respiratory season and if the respiratory season is less severe than anticipated, demand may be adversely impacted." This is a Q1 2026 forward-looking risk on the Cepheid molecular diagnostics franchise.

5. Goodwill Concentration Across Three Reporting Units — With $43.2B in goodwill spread primarily across the Cytiva, Beckman Coulter, Cepheid, Abcam, and Aldevron reporting units, any prolonged weakness in bioprocessing demand or life-sciences research funding could trigger further impairment. The 2025 $562M charge shows the process is active, not dormant.

6. Uncertain Tax Positions — The CAM identified by E&Y ($1.3B in gross unrecognized tax benefits) is a standard multinational exposure, but the magnitude (~36% of 2025 net earnings) is significant. Tax audits in any major jurisdiction could materially shift reported results.

7. Healthcare Reimbursement Regulation — From the 10-K: "Medicare, Medicaid and comparable non-U.S. programs, private insurance plans and managed care plans, for the healthcare services provided to their patients. The ability of our customers to obtain appropriate reimbursement for products and services from third-party payers is critical because it affects which products customers purchase and the prices they are willing to pay."

Summary

Grade: F. Clean accounting, strong cash flow, structural balance sheet stress from serial acquisitions.

Danaher's 2025 financial statements are honestly prepared — E&Y has served as auditor since 2002, issued an unqualified opinion, and the Critical Audit Matter is the standard uncertain-tax-positions item for a multinational of Danaher's size. CFFO of $6.4B, FCF of $5.26B, and a 21% FCF margin are among the strongest in healthcare. The Beneish M-Score of -2.57 is clean, the F-Score probability of misstatement is 0.60%, and Altman Z-Score is 4.45 in the safe zone.

The F grade is mechanical and entirely driven by Danaher's 25-year acquisition strategy: $43.2B in goodwill plus $17.8B in intangibles equals $61.0B against $52.5B of book equity (116% ratio). This is the legacy of Beckman Coulter, Pall, Cepheid, Cytiva, Aldevron, and Abcam — a portfolio built on premium prices during the 2010-2023 acquisition cycle. Cash of $4.6B against $19.7B of debt (23% coverage) is the second structural flag.

What makes 2025 a transitional year is the combination of (a) $562M in intangible asset impairments — up from $265M in 2024 — concentrated in the Life Sciences segment, (b) 2.9% revenue growth as bioprocessing recovers but Life Sciences flatlines, (c) the pending Masimo acquisition, and (d) explicit tariff headwinds being "largely offset" through operational levers. Net earnings from continuing operations declined from $3.9B to $3.6B.

The 10-K is the right read for anyone trying to understand Danaher: management is transparent about the earnings decline drivers, the tariff environment, the pending Masimo deal, and the respiratory-test seasonality risk. Bioprocessing's 8% segment growth is the bright spot — the Cytiva acquisition thesis remains intact, and consumables-led growth is a better leading indicator than equipment. But buying Danaher today is betting that Masimo integrates well, Life Sciences avoids further impairments, tariffs remain "largely offset," and bioprocessing re-acceleration continues into 2026.

**Disclaimer**: This report is based on Danaher's 2025 10-K (SEC EDGAR, filed 2026-02-24) and public financial data. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags. Grade F means major red flags were detected that require serious investigation before proceeding.